Basically, Fresenius has not done anything wrong. Management delivered its increased guidance, it reported progress in the cost-cutting programme and it gave a promising outlook. However, investors might have hoped for something larger, e.g. the divestment of the FMC stake or the separation of Kabi, but management remained true to itself.
Figures were a clear beat to our estimates (sales: +5.9%; profitability: +9.8%) as we had booked some higher costs for the cost-cutting programme.

28 Feb 2022
Capital market’s disbelief

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Capital market’s disbelief
Basically, Fresenius has not done anything wrong. Management delivered its increased guidance, it reported progress in the cost-cutting programme and it gave a promising outlook. However, investors might have hoped for something larger, e.g. the divestment of the FMC stake or the separation of Kabi, but management remained true to itself.
Figures were a clear beat to our estimates (sales: +5.9%; profitability: +9.8%) as we had booked some higher costs for the cost-cutting programme.